Document is current
Any future updates will be listed below
-
Authors
Tripathi, Prabhanshu
Koo, Ja-Hyun
Chen, Xuejun
Silva Pereira, Lais Da
Dillon, Marlon
Zhang, Baoshan
Lofgren, Mariah
Nguyen, Katelyn T.
Teng, I-Ting
Bonilla, Brian
Kerscher, Sarah
Kong, Wing-Pui
Henry, Amy R.
Stephens, Tyler
Tsybovsky, Yaroslav
Weldon, Stephanie R.
Douek, Daniel C.
Pierson, Theodore C.
Batista, Facundo D.
Idris, Azza H.
Seder, Robert A.
Kwong, Peter D.
Zhou, Tongqing
-
Funding
Funding for this research was provided by:
Intramural Research Program
- License Information
-
More Information
Article History
Received: 1 October 2025
Accepted: 9 April 2026
First Online: 27 April 2026
Competing interests
: The NIH has submitted on behalf of R.A.S., P.D.K., P.T., and B.Z. a US Provisional Patent Application E-237-2024-0-US-01, filed on April 16th, 2025, describing the nanoparticle immunogens and their use. All other authors declare no competing interests. F.D.B. has consultancy relationships with Adimab, Third Rock Ventures, and The EMBO Journal and founded BliNK Therapeutics.
